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 Abstract  
The a7 nicotinic acetylcholine receptor (nAChR) is a potential drug target for the 
treatment of a number of neurological and inflammatory disorders. Silent agonists are an 
emerging class of drugs that bind to the receptor but do not open the channel. Instead 
they shift the receptor to a desensitized state. Silent agonists may be able to target a 
subset of a7 nAChR mediated signaling processes. Here we use non-canonical amino 
acid mutagenesis to characterize the binding to a7 by the silent agonist NS6740. We find 
that like a7 agonists, NS6740 forms a cation-p interaction with Y115 (TyrA). We also 
showed that NS6740 makes a novel hydrogen bond to TyrA. This interaction is necessary 
for the silent agonist activity of NS6740; when the hydrogen bond is blocked silent agonist 
NS6740 converts to a conventional partial agonist and appreciably opens the channel in 
the absence of a positive allosteric modulator (EC50 150 nM).  
 
Significance Statement 
 Noncanonical amino acids were used to show that a hydrogen bond to tyrosine (Y115) is 
required for silent agonist activity of NS6740 at the a7 nicotinic acetylcholine receptor.  
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Introduction 
The homopentameric a7 nicotinic acetylcholine receptor (nAChR) is a ligand gated 
ion channel characterized by low opening probability due to rapid, agonist concentration-
dependent desensitization (Williams et al., 2011, 2012; Papke, 2014; Corradi and Bouzat, 
2016). The a7 nAChR is the second most abundant nAChR in the brain and is expressed 
both synaptically and non-synaptically, as well as in nonneuronal cells (Corradi and 
Bouzat, 2016). It has been implicated as a drug target for the treatment of schizophrenia, 
pain and inflammation, among other neurological disorders (Dineley et al., 2015; Egea et 
al., 2015).    
Classically, a7 nAChR-mediated signaling occurs because ligand binding triggers 
the channel to open, allowing ion influx and generating an electric current across the 
membrane. Recent studies suggest that a7 may exhibit ligand-mediated metabotropic 
signal transduction, independent of ion channel opening (King et al., 2015; Kabbani and 
Nichols, 2018). One way to potentially study metabotropic signaling occurring from a 
desensitized state is by using silent agonists.  
Silent agonists are a novel class of drugs that, upon binding, do not open the 
channel but rather induce a conformational change stabilizing a desensitized state (Fig. 
1). This can be confirmed by the co-application of a type 2 positive allosteric modulator 
(PAM) such as PNU-120596, which shifts the equilibrium toward a conducting open state, 
presumably by destabilizing the desensitized state and/or stabilizing the open state. It has 
been proposed that the desensitized and open states associated with a silent agonist are 
different from those associated with a conventional agonist (Papke et al., 2014, 2018). 
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Silent agonists should not be thought of as competitive antagonists. Competitive 
antagonists simply block agonist binding and do not induce a conformational change that 
is sensitive to binding of a type 2 PAM.   
The first silent agonist to be characterized, NS6740 (Briggs et al., 2009), has been 
shown in vitro to modulate the inflammatory response of microglia cells as part of the 
cholinergic anti-inflammatory pathway (Thomsen and Mikkelsen, 2012) and reduce the 
symptoms of neuropathic pain in mouse models (Papke et al., 2015). Another silent 
agonist, PMP-072, was shown in mouse models to have anti-arthritic effects (Van 
Maanen et al., 2015). The fact that these drugs are able to induce a physiological 
response despite not being able to open the channel supports the proposed metabotropic 
signaling pathway for a7. If true, silent agonists represent novel therapeutic agents for 
the selective targeting of a specific subset of a7-meditated signaling pathways, such as 
those related to chronic inflammation and neuropathic pain (Horenstein and Papke, 
2017).  
Little is known about the core pharmacophore of silent agonists, and a better 
understanding of the binding of silent agonists could guide the design of new silent 
agonists. So far all characterized silent agonists at a7 nAChR have a cationic nitrogen, 
either a protonatable amine or a quaternary ammonium, and are believed to bind at the 
orthosteric site (Papke et al., 2015). Initial studies on alkylammonium ligands showed that 
increasing bulk around the cation reduced agonist activity while maintaining 
desensitization activity (Papke et al., 2014; Quadri et al., 2016). NS6740 has a bulky 
bicyclo[3.2.2] ring system, but derivatives of NS6740 lacking the bulky bicyclic ring system 
still exhibit silent agonist activity (Chojnacka et al., 2013). 
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There is currently no atomic scale structural information for the full a7 receptor, let 
alone in the open, closed and desensitized states. a7-chimeric AChBP crystal structures 
give some insight into the orthosteric binding site (Li et al., 2011; Nemecz and Taylor, 
2011). However, it is unclear if these represent an open or desensitized state, and there 
is no crystal structure of a silent agonist bound. High resolution electrophysiology can be 
used to gain vital structure-function information on ion channels. However, silent agonists 
require a PAM to generate an electrophysiological signal, complicating matters.  
This study uses noncanonical amino acid mutagenesis (Fig. 2) to probe the binding 
of the silent agonist NS6740 at the orthosteric site of the a7 nAChR (Dougherty, 2013, 
Van Arnam and Dougherty, 2014) and compares the results to previous work from our 
lab on the binding of typical agonists such as acetylcholine (ACh) and nicotine (Marotta 
et al., 2015). We find that the silent agonist NS6740 makes a cation-π interaction to TyrA 
and a never before characterized, functionally significant hydrogen bond with TyrA.  
 
Materials and Methods  
Molecular Biology. The rat nAChR a7 subunit (pAMV vector), Ric3 (pAMV 
vector), and NACHO (pAMV vector), were used as the bases for all constructs. Residue 
numbering was based on the full-length protein containing the signaling sequence as 
found on the UniProt database (Q05941). Site directed mutagenesis was performed by 
PCR using the Stratagene QuikChange protocol with primers from Integrated DNA 
Technologies. The circular cDNA plasmids were linearized with NotI-HF (New England 
BioLabs) and purified (Qiagen). DNA was then transcribed in vitro using the T7 
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mMessage Machine kit (Ambion) and the mRNA was isolated using the RNeasy 
purification kit (Qiagen). The Amber (UAG) stop codon was used for incorporating 
noncanonical amino acids in the a7 subunit. The 74-nucleotide THG73 tRNA and 76-
nucleotide THG73 tRNA were in vitro transcribed using the MEGAshortscript T7 (Ambion) 
kit and isolated using CHROMA SPIN DEPC-H2O columns (Clontech). Final 
concentrations were determined by UV-Vis.  
Oocyte Preparation and Injection. Xenopus laevis oocytes (stage IV and V) were 
retrieved as described previously (Nowak et al., 1998). For conventional mutagenesis 
experiments, a7 and Ric3 mRNA were mixed 1:1 by weight and oocytes were injected 
with 50 nL solution containing 20 ng mRNA. Cells were incubated at 18 °C for 24 hrs in 
ND96 solution (96 mM NaCl, 1.8mM CaCl2, 2 mM KCl, 1mM MgCl2, 5 mM HEPES at pH 
7.5) enriched with theophylline (6.7 mM), sodium pyruvate (2.5 mM) and kanamycin (0.1 
mg/ml). Kanamycin was used because other antibiotics have been shown to reduce a7 
expression levels (Amici et al., 2005). 
Noncanonical amino acid incorporation. The NVOC protected, 
cyanomethylester form of the noncanonical amino acid was coupled to the dinucleotide 
dCA and enzymatically ligated to the UAG-suppressor 74-mer THG73 tRNACUA. The 
product was verified via matrix assisted laser desorption/ionization (MALDI) time of flight 
mass spectrometry using a 3-hydroxypicolinic acid matrix (Nowak et al., 1998). The 
noncanonical amino acid-coupled tRNA was deprotected with a M365LP1 365 nm 1150 
mW LED lamp (Thor Labs) immediately before co-injection with mRNA containing a UAG 
mutation at the site of interest. mRNA and tRNA were injected in a 1:1 or 2:1 volume ratio 
in a total volume of 50 or 75 nL respectively so that cells were injected with a 40 ng 1:1 
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mixture of a7-UAG and Ric3 mRNA. For noncanonical amino acids that showed little or 
no response after 24 hr incubation, oocytes were subjected to a second round of injection 
and incubation as before. If this procedure was not effective, oocytes were double injected 
with a 75nL solution containing 40 ng mRNA of a7-UAG, Ric3 and NACHO 1:1:1 mixture. 
A read-through/reaminoacylation test served as a negative control. Full length unacylated 
76-mer tRNA was co-injected with mRNA. Lack of current showed no detectable 
reaminoacylation at the suppression site.  
Drug Preparation. Acetylcholine chloride (Sigma-Aldrich) was dissolved in ND96 
Buffer to make a 1M stock solution. NS6740 was synthesized as described previously 
(Papke et al., 2015) and dissolved in DMSO to form a 20 mM stock solution. PNU-120596 
(Selleckchem) was dissolved in DMSO to 150 mM stock. Further dilutions were made for 
experimentation using ND96 Buffer.   
Electrophysiology. Agonist-induced currents were recorded using an 
OpusXpress 6000A (Axon Instruments/Molecular Devices) in TEVC mode at a voltage 
clamped holding potential of -60 mV. Voltage and current electrodes were filled with 3M 
KCl. Oocytes were perfused with ND96 media at a rate of 3 ml/minute. Drug applications 
consisted of co-application of 1 mL dose of drug solution over 8 seconds followed by 15 
second pause to allow response to reach maximum before being washed out for 300 
seconds at a rate of 3 ml/min (Supplemental Table S1 and Fig. S1). Concentrations of 
NS6740 were varied over several orders of magnitude to generate a concentration-
response curve. For efficacy experiments 1 mL of EC100 dose of drug was applied over 8 
seconds followed by a 1 minute incubation followed by 10 minute washout.    
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Data Analysis. Data were sampled at 50 Hz and then low pass filtered at 5Hz. For 
NS6740 co-applied with PNU-120596 EC50 measurements were recorded as peak height. 
Data for concentration response curves were baselined, and normalized on a per cell 
basis, and then averaged on a per-concentration basis and the Hill equation was fit to the 
data using Prism 6 (GraphPad Software). EC50 and Hill coefficient errors are presented 
as SE. For relative efficacy experiments ACh doses were normalized to an initial ACh 
dose and all other drug applications were normalized to an immediately preceding 
acetylcholine dose and reported as Rmax=Imax(drug)/Imax(ACh). In data tables N refers to 
the total number of oocytes analyzed. Cells from different frogs on at least two different 
days were used for each point; if N < 10 then cells from a third frog on a third day were 
injected. Cation-p binding energies were calculated, ab initio (6-311G**), for a gas phase 
Na+ ion binding to each non canonical amino acid side chain as described previously 
(Duffy, 2014).  
 
Results  
Measuring Binding interactions in the presence of a PAM. Our metric for 
measuring the effect of noncanonical amino acid incorporation is the half-maximal 
effective concentration (EC50). This is a composite measure of several equilibria, including 
agonist binding and channel gating events. There is some ambiguity about how a given 
mutation in a protein shifts EC50, affecting either gating or binding. Single channel 
measurements can provide more detailed kinetic analysis on which equilibrium is being 
perturbed. However, single channel studies are not feasible in this study, given the 
number of mutations probed and protein expression limitations for a7.  
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Given that noncanonical amino acid mutagenesis allows for very subtle and 
precise modifications of the protein and given our knowledge of the structure of the 
binding site, it is clear we are probing interactions within the binding site, and that shifts 
in EC50 are a result of attenuated binding interactions. The ambiguity concerns which of 
the multiple equilibria is most perturbed by the mutation, but it is clear we are perturbing 
binding interactions between the drug and the protein.  
 A complicating factor in this project is the need to co-apply a PAM with the silent 
agonist of interest for a signal to be observed. In ion channels, allosteric modulators can 
induce a long-range conformational change to the orthosteric binding site, altering the 
binding affinity of the agonist, or they can modulate the gating transition of the receptor. 
If the former mechanism were operative, it would complicate analysis of a silent agonist. 
However, we have previously shown that in a7 the type 2 PAM PNU-120596 does not 
alter the orthosteric binding site, as determined by detailed interactions with the native 
agonist ACh (Marotta et al., 2015). This was done by comparing the impact of a mutation 
on receptor function with or without the co-application of the PAM. Given that PNU-
120596 does not alter the agonist binding site, we can assume that any change from 
mutations made to the binding site are from an interaction with NS6740 not PNU-120596. 
As such, studies of NS6740 were performed in the presence of 10 µM PNU-120596, 
producing robust signals in our Xenopus oocyte assay. 
Binding interaction of TyrA with NS6740. While the cation-p interaction plays a 
prominent role in binding of natural and synthetic agonists to nAChRs (and other Cys-
loop receptors), a7 is unique in the family in that ACh makes a cation-p interaction with 
TyrA (Y115, so named because it lies on loop A of the agonist binding site), rather than 
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on June 7, 2019 as DOI: 10.1124/mol.119.116244
 at A
SPET Journals on June 17, 2019
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL # 113019 
 11 
TrpB (W171), the more commonly used residue (Puskar et al., 2011; Van Arnam and 
Dougherty, 2014). It is possible to identify a cation-p interaction by progressively 
fluorinating the aromatic group, reducing the p electron density of the aromatic ring 
surface, and thus weakening the interaction. When plotted against calculated cation-p 
binding energies, this results in a “fluorination” plot. This approach also applies to other 
deactivating substituents on the aromatic side chain, including cyano and bromo 
functional groups. However, fluorination affects the pKa of the hydroxyl functional group 
of tyrosine as well as the strength of the cation-p interaction. Therefore, to study tyrosine 
residues, such as TyrA, it is necessary to either methylate the hydroxyl group, producing 
TyrOMe, or remove the hydroxyl group entirely and use Phe derivatives. We employed 
both strategies here. 
The fluorination plot shows a linear relationship indicating that NS6740 forms a 
cation-p interaction with TyrA (Table 1, Fig. 3). The slope of the fluorination plot (-0.16 ± 
0.03) is similar to that of acetylcholine (-0.15 ± 0.02) at TyrA for a7 (Marotta et al., 2015). 
This suggests a similar strength of interaction, despite the increased bulkiness of the 
ligand. Using acetylcholine, we have previously shown that a sterically significant 
substituent is needed at the 4-position of the A-site residue (Puskar et al., 2011; Marotta 
et al., 2015). This effect is less pronounced for NS6740 but still noticeable, with Phe and 
4-F1Phe not falling on the line. 
A novel observation is that TyrA forms a functionally relevant hydrogen bond for 
activation of NS6740. A large gain of function was observed when Tyr was replaced by 
TyrOMe (Table 1). The hydroxyl group of TyrA can act as both a hydrogen bond donor 
and acceptor. Methylation of the hydroxyl group removes the hydrogen bond donating 
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ability of the residue but not its hydrogen bond accepting ability. Note that activation by 
ACh is unaffected by the Tyr-to-TyrOMe mutation, both in the presence or absence of 
PNU-120596 (Marotta et al., 2015). While we have seen a loss of function for this mutation 
before (Nowak et al., 1995; Lummis et al., 2005; Daeffler et al., 2014), most notably in 
muscle type nAChR, this is the first time we have ever seen gain of function for TyrOMe.  
The shift in EC50 was accompanied by an increase in relative efficacy for the 
NS6740/PNU-120596 combination, being 1.9±0.32 for the TyrOMe mutant vs. 
0.027±0.004 for the wild type, relative to activation by ACh (Table 2). A comparable effect 
was not seen when judging the impact of PNU-120596 on ACh activation – wild type and 
the TyrOMe mutant show only a small difference.  
The increase in efficacy for the TyrOMe mutant was so great, we hypothesized 
that the PAM PNU-120596 may no longer be needed for NS6740 to open the channel 
(Table 3, Fig. 4). This proved to be true, as NS6740 acts as partial agonist on the mutant 
channel with an EC50 of 150 nM. The shape of the signal changed in the absence of PNU-
120596 to resemble a much more traditional a7 agonist trace, which is characterized by 
its sharp peak and fast desensitization (Fig. 4). This is understandable, given that PNU-
120596 acts by disrupting the desensitized state, resulting in broader signals when co-
applied with an agonist.  
During efficacy experiments, no suppression of signal for applications of ACh after 
application of NS6740 were observed for wild type receptors in contrast to previous work, 
which indicated NS6740 had a slow binding off rate (Papke et al., 2018). This is most 
likely due to variations in experimental set up. However, for the TyrOMe mutation a 
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significant decrease in the efficacy of ACh after application of NS6740 was observed. 
This indicates that TyrOMe may lower the binding off rate for NS6740. 
Characterization of other binding interactions of NS6740 in the orthosteric 
binding site: Other potential cation-π sites. Previous work has shown that the high 
affinity agonist epibatidine makes a cation-p interaction with TyrC2 (Y217) at a7 in 
addition to the cation-π interaction at TyrA (Puskar et al., 2011). Low currents (Table 1) 
prevented a complete study of TyrC2; no signal was detected for more strongly perturbing 
residues such as 4-CNPhe or 2,3,5,6-F4TyrOMe. However, it is still clear that NS6740 
does not make a strong cation-p interaction (Fig. 3); the most perturbing residue 
measured, 4-BrPhe, was essentially wild type.  
Acetylcholine also does not form a cation-p interaction at TyrC2, but two trends 
were noted. First, bulk is required at the 4 position for ACh binding (Marotta et al., 2015). 
This is not true for NS6740 - Phe and TyrOMe have similar fold shits, 0.96 and 0.74 
respectively. This may be because NS6740 is bulkier and compensates for the loss of 
bulk at the 4 position. Secondly, TyrC2 is sensitive to 3- or 5- substitutions on the ring 
system for ACh binding (Marotta et al., 2015). This is also true for NS6740; the largest 
losses of function at TyrC2 were for 3-F1TyrOMe and 3,5-F2TyrOMe. However, the 
magnitude of the effect was much smaller (approximately 2.5-fold for NS6740 compared 
to greater than 10-fold for ACh). Again, bulk of the silent agonist may explain this. Overall, 
interaction of NS6740 with TyrC2 does not appear to play an important functional role. 
 We have also probed other members of the aromatic box, and we find that NS6740 
does not make meaningful interactions with any of the other residues. Insertion of the 
highly perturbing residue F3Trp at TrpB resulted in a modest 5.5-fold shift (Table 1) 
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indicating, at best, a very weak interaction. Substitution by F3Trp at TrpD (W77) showed 
a slight gain of function, consistent with observations for acetylcholine binding to a7 
(Table 1). TrpD has never been implicated in a cation-p interaction with an agonist in any 
nAChR. TyrC1 (Y210), the final aromatic residue that composes the classical binding box, 
was not probed, because historically any perturbation at this site has resulted in very large 
losses of function (Puskar et al., 2011), and it has never been implicated in a cation-p 
interaction in any Cys-loop receptor (Van Arnam and Dougherty, 2014).  
Backbone Hydrogen Bonding at the orthosteric binding site. Next we looked 
at important backbone hydrogen bonding interactions within the orthosteric binding site. 
Incorporation of a-hydroxy analogs at appropriate locations eliminates the hydrogen bond 
donating backbone NH and weakens the hydrogen bonding ability of the carbonyl (i-1) by 
converting it to an ester (Fig. 2). This assay allows for the study of functionally relevant 
hydrogen bonds only: crystal structures may show the presence of a hydrogen bond but 
EC50 will only show a shift if that hydrogen bond is functionally relevant.  
Two agonist-backbone hydrogen bonds historically have been found to be 
functionally relevant to agonist binding in nAChRs. The carbonyl of TrpB forms a 
hydrogen bond with non-quaternary amine cation agonists. This is true for NS6740 as 
well (Table 1, S172). Second, L141 acts as a hydrogen bond donor for many agonists of 
nAChRs, and at a7 it forms a functionally relevant hydrogen bond for epibatidine but not 
acetylcholine or varenicline (Van Arnam et al., 2013). NS6740 does not make a 
functionally relevant hydrogen bond at this site (Table 1).  
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Discussion: 
This work focuses on the binding interactions of the silent agonist NS6740 at the 
a7 nAChR. Noncanonical amino acids were used to probe the orthosteric site, and the 
results for NS6740 –in the presence of the Type 2 PAM PNU-120596 - were compared 
to the endogenous agonist ACh. This resulted in three major findings: first, we confirmed 
that NS6740 binds at the orthosteric site; second, TyrA forms a hydrogen bond that 
discourages activation in the presence of NS6740, and this hydrogen bond is a 
requirement for silent agonist activity; and third, NS6740 forms a cation-p interaction with 
TyrA, consistent with several agonists of a7.  
It was predicted that NS6740 binds at least partially in the orthosteric binding site, 
given the cationic nitrogen at physiological pH and competitive inhibition of the native 
agonist (Papke et al., 2015). Using noncanonical amino acids to probe binding 
interactions of the orthosteric binding site, we showed that NS6740 does indeed bind at 
the orthosteric binding site. This is evidenced by the cation-p interaction to TyrA and 
hydrogen bonds to TyrA and to the backbone carbonyl of TrpB. This is the most direct 
evidence so far concerning the binding site of NS6740. Furthermore, we observe subtle 
differences in those interactions that give insight into the nature of silent agonist binding.    
 An intriguing finding of the present work is the key role of a hydrogen bond 
involving the OH of TyrA as the donor. This was revealed by the strong impact of the 
TyrOMe mutation, an effect not seen with this substitution in other studies. This relatively 
subtle mutation profoundly impacts receptor response to NS6740, turning the silent 
agonist – which produces no signal on its own – to a conventional partial agonist. In 
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principle, the hydrogen bond acceptor could be another side chain residue, the protein 
backbone, or the silent agonist itself. We propose that the most likely hydrogen bonding 
partner is the amide carbonyl of NS6740. Related compounds lacking the amide carbonyl, 
but maintaining a similar overall structure, have been reported in the literature as partial 
agonists of a7 (Briggs et al., 2009), supporting the importance of the carbonyl of NS6740 
to its silent agonist activity. Secondly, the distance between the cationic nitrogen and 
carbonyl of NS6740 is ~5.9Å. Recall that the N+H of NS6740 makes a hydrogen bond to 
the backbone carbonyl of TrpB. While there is some variability, a typical distance 
observed in x-ray crystal structures between the backbone carbonyl of TrpB and the TyrA 
OH is 5.8Å, as seen the in apo structure of the a7-AChBP chimera crystal structures (Li 
et al., 2011). This suggests that the receptor could easily adapt to form an arrangement 
such as shown in Figure 5. We propose that the hydrogen bond between the carbonyl of 
NS6740 and the OH of TyrA locks the receptor closed or in an alternative desensitized 
state (D*). Removal of the TyrA OH, by making TyrOMe, removes this interaction and 
turns NS6740 into a partial agonist. Additionally, removal of the Tyr OH appears to lower 
the binding off rate for NS6740 which further indicates an altered binding site. 
 Figure 6 presents a simplified model to describe the results reported here. ACh 
stabilizes the open state (O), enabling channel activation. In the a7 nAChR, the 
desensitized state D is readily reached via either the open or the closed ACh-bound state 
(the latter path is not shown in Fig. 6). A silent agonist such as NS6740 is thought to 
stabilize an alternative desensitized state, D*, which cannot gate (Papke et al., 2018). 
Addition of a type 2 PAM such as PNU-120596 destabilizes D* and/or stabilizes an 
alternative open state, O*, allowing channel gating. The TyrA to TyrOMe mutation results 
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in a sharp peak (Fig. 4b), typical of normal agonist activity and fast desensitization, 
indicating that removal of the hydrogen bond results in NS6740 stabilizing a more typical 
open state and acting on its own as a partial agonist. Figure 6 shows the mutation acting 
in a manner similar to that of ACh, but other mechanisms are possible.  
The final major finding is that, like all agonists tested at a7, NS6740 forms a cation 
π interaction to TyrA. A typical dependence of EC50 on the cation-p binding ability of the 
residue at the TyrA position is seen (Fig. 3). A caveat is that, when probing for a cation-
π interaction at TyrA, we have altered the OH of the Tyr so that the hydrogen bond of 
Figure 5 does not form. It is conceivable that this change turns on a cation-π interaction 
that is absent in the wild type receptor. We consider this unlikely, since no other aromatic 
residue shows a cation-p interaction, and a cation-p interaction to TyrA is a universal 
feature of compounds that activate the a7 nAChR.  
We have used noncanonical amino acids and nonsense suppression to probe the 
binding of NS6740, a silent agonist. This is the first structure-function study of a silent 
agonist, and we showed that a specific hydrogen bond inhibits agonist activity and is 
important for suppressing channel opening for silent agonists.  Given these results, in the 
future it may be possible to probe the desensitized state using nonsense suppression and 
silent agonists.  
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Legends for Figures 
 
Figure 1. Silent agonist activity. A) Representative current trace for the application of 
acetylcholine (ACh) on a7. B) Representative current trace shapes for application of the 
silent agonist, NS6740, on a7 and the co-application of NS6740 and the type 2 positive 
allosteric modulator (PAM) PNU-120596. C) Structures of NS6740 and PNU-120596. 
 
Figure 2. Structures of the side chains of noncanonical amino acids used in this work. A) 
Tyrosine derivatives. B) Tryptophan derivatives. C) Backbone amide to ester mutation 
strategy for perturbing a hydrogen bond.   
 
Figure 3. Cation-p plots for TyrA and TyrC2 in the a7 nicotine acetylcholine receptor 
(nAChR). A) NS6740 forms a cation-p interaction at TyrA in the presence of PNU-
120596 with a similar strength to acetylcholine (ACh) at TyrA, as indicated by the slopes 
of linear regression fit to the Log10[EC50(mut)/EC50(wt)] (NS6740, -0.16 ± 0.03 and ACh -
0.15 ± 0.02). B) TyrC2 shows no cation-π interaction with NS6740 or acetylcholine. 
Acetylcholine data are from (Marotta, et al., 2015). 
 
Figure 4. Effect of the a7 TyrA TyrOMe mutation on NS6740 activity. A) EC50 curve for 
application of NS6740 on a7 TyrA TyrOMe without any type 2 PAM. B) Representative 
current traces for NS6740 on a7 TyrA TyrOMe. C) Representative current traces for 
NS6740 on a7 wild type receptors. 
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Figure 5. Scheme of purposed binding interactions of NS6740 at the orthosteric binding 
site of a7 nAChR. Showing a hydrogen bond and a cation-p interaction to TyrA and a 
hydrogen bond to TrpB.  
 
Figure 6. Schematic summarizing the results described here. The scheme is based in 
part on previously published models of Papke (Papke et al.,2018). Shown are the 
conventional closed (C), open (O), and desensitized (D) states, as well as alternative 
desensitized and open states (D* and O*) that are accessed by a silent agonist. 
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Tables 
Table 1: EC50 Values of Aromatic Box Residues 
α7  
 
NS6740 + PNU-120596 (10 µM) 
Mutation   pEC50(± SE) EC50 (nM) Hill (± SE) Imax (µA) Fold Shift From WT n 
WT   7.208 ± 0.031 62 1.9 ± 0.21 0.24-2.4 - 13 
TyrA              
   TyrOMe  8.445 ± 0.023 3.6 3 ± 0.41 0.33-34 0.06 10 
   3-F1TyrOMe 8.035 ± 0.053 9.2 2 ± 0.41 0.19-25 0.15 11 
   3,5-F2TyrOMe 7.918 ± 0.051 12 2 ± 0.41 0.43-39 0.2 12 
   4-BrPhe  8.145 ± 0.025 7.2 2.7 ± 0.31 0.13-25 0.12 13 
   4-CNPhe  7.146 ± 0.017 71 3.1 ± 0.27 2.9-32 1.2 13 
   2,3,5,6-F4TyrOMe 5.883 ± 0.038 1300 3.4 ± 0.74 0.01-1.6 21 10 
   Phe  8.041 ± 0.019 9.1 2.9 ± 0.34 1.2-16 0.15 14 
   4-MePhe  7.92 ± 0.02 12 2.5 ± 0.28 0.01-0.29 0.19 13 
   4-F1Phe   6.72 ± 0.017 190 2.1 ± 0.15 0.13-2.7 3.1 13 
TrpB              
   Trp  7.182 ± 0.023 66 2.4 ± 0.25 0.06-0.46 1.1 13 
   F3Trp   6.466 ± 0.013 340 2.3 ± 0.12 0.02-6.8 5.5 14 
TyrC2              
   Phe  7.218 ± 0.072 60 2 ± 0.33 0.01-0.41 0.96 13 
   TyrOMe  7.344 ± 0.029 46 2.2 ± 0.26 0.01-0.08 0.74 10 
   4-F1Phe  7.069 ± 0.051 85 1.9 ± 0.32 0.01-0.02 1.4 11 
   3-F1TyrOMe 6.744 ± 0.021 160 2.3 ± 0.17 0.01-0.27 2.7 13 
   3,5-F2TyrOMe 6.802 ± 0.33 160 2.7 ± 0.43 0.01-0.12 2.5 11 
   4-BrPhe   7.375 ± 0.075 38 1.6 ± 0.26 0.02-0.13 0.6 10 
TrpD              
   Trp  7.045 ± 0.034 90 1.8 ± 0.22 0.01-0.15 1.4 13 
   F3Trp   8.037 ± 0.017 9.2 3.1 ± 0.39 0.53-9.5 0.15 12 
Ser172              
   Thr  7.247 ± 0.034 57 1.8 ± 0.21 1.2-44 1 11 
   Tah   6.299 ± 0.028 500 2.6 ± 0.31 0.66-41 7.6 16 
Leu 114              
   Leu  7.108 ± 0.042 78 2.9 ± 0.2 0.04-12 1.3 18 
   Lah   7.056 ± 0.028 88 1.6 ± 0.024 0.01-0.60 1.4 8 
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Table 2: Relative Efficacy to Imax Acetylcholine (SEM) 
Drug  WT n TyrA/TyrOMe n 
NS6740     0.13 ± 0.1 15 
ACh 1.00 ± 0.039 19 0.325 ± 0.056 16 
NS6740+PNU-
120596 0.027 ± 0.004 19 1.9 ± 0.32 16 
ACh 1.25 ± 0.10 19 0.60 ± 0.071 16 
ACh+PNU-120596 1.4 ± 0.18 18 2.1 ± 0.34 16 
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Table 3: EC50 Values at TyrA:TyrOMe 
Drug pEC50 (± SE) Hill (± SE) Imax (µA) n 
NS6740 6.838 ± 0.067 1.7 ± 0.37 0.052-1.8 10 
NS6740+PNU-120596 8.445 ± 0.023 3.0 ± 0.41 0.33-35 10 
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Figure 1  
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
 
 
  
N
N+
H
O
TrpB
N
H
TyrA
O O
ArO H
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on June 7, 2019 as DOI: 10.1124/mol.119.116244
 at A
SPET Journals on June 17, 2019
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
  31 
Figure 6 
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